Literature DB >> 26650572

Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Sara Di Lorenzo1, Daniele Fanale2, Bartolo Corradino1, Valentina Caló2, Gaetana Rinaldi2, Viviana Bazan2, Antonio Giordano3, Adriana Cordova1, Antonio Russo2.   

Abstract

Germline CDKN2A mutations have been described in 25% to 40% of melanoma families from several countries. Sicilian population is genetically different from the people of Europe and Northern Italy because of its historical background, therefore familial melanoma could be due to genes different from high-penetrance CDKN2A gene. Four hundred patients with cutaneous melanoma were observed in a 6-years period at the Plastic Surgery Unit of the University of Palermo. Forty-eight patients have met the criteria of the Italian Society of Human Genetics (SIGU) for the diagnosis of familial melanoma and were screened for CDKN2A and CDK4 mutations. Mutation testing revealed that none of the families carried mutations in CDK4 and only one patient harboured the rare CDKN2A p.R87W mutation. Unlike other studies, we have not found high mutation rate of CDKN2A in patients affected by familial melanoma or multiple melanoma. This difference could be attributed to different factors, including the genetic heterogeneity of the Sicilian population. It is likely that, as in the Australian people, the inheritance of familial melanoma in this island of the Mediterranean Sea is due to intermediate/low-penetrance susceptibility genes, which, together with environmental factors (as latitude and sun exposure), could determine the occurrence of melanoma.

Entities:  

Keywords:  CDKN2A; cutaneous melanoma; familial melanoma; germline mutation; p.R87W mutation; p14ARF; p16INK4a

Mesh:

Substances:

Year:  2016        PMID: 26650572      PMCID: PMC4847825          DOI: 10.1080/15384047.2015.1108494

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  68 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.

Authors:  Y Cheli; S Giuliano; S Guiliano; T Botton; S Rocchi; V Hofman; P Hofman; P Bahadoran; C Bertolotto; R Ballotti
Journal:  Oncogene       Date:  2011-01-31       Impact factor: 9.867

3.  High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.

Authors:  Michela Mantelli; Monica Barile; Paola Ciotti; Paola Ghiorzo; Francesca Lantieri; Lorenza Pastorino; Caterina Catricalà; Gabriella Della Torre; Ugo Folco; Paola Grammatico; Laura Padovani; Barbara Pasini; Dario Rovini; Paola Queirolo; Maria Luisa Rainero; Pier Luigi Santi; Roberto M Sertoli; Alisa M Goldstein; Giovanna Bianchi-Scarrà
Journal:  Am J Med Genet       Date:  2002-01-22

Review 4.  Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.

Authors:  Shilpa Bhatia; Luni Emdad; Swadesh K Das; Hossein Hamed; Paul Dent; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Investig Drugs       Date:  2014-02-06       Impact factor: 6.206

5.  Role of the CDKN2A locus in patients with multiple primary melanomas.

Authors:  Susana Puig; Josep Malvehy; Cèlia Badenas; Anna Ruiz; Dolores Jimenez; Francisco Cuellar; Antoni Azon; Urbá Gonzàlez; Teresa Castel; Antoni Campoy; Josep Herrero; Rosa Martí; Joan Brunet-Vidal; Montserrat Milà
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

6.  The genetic heterogeneity of β-globin gene defects in Sicily reflects the historic population migrations of the island.

Authors:  Antonino Giambona; Margherita Vinciguerra; Monica Cannata; Filippo Cassarà; Germana Fiorentino; Filippo Leto; Pina Lo Gioco; Disma Renda; Cristina Passarello; Aurelio Maggio
Journal:  Blood Cells Mol Dis       Date:  2011-02-24       Impact factor: 3.039

7.  Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.

Authors:  V Nikolaou; X Kang; A Stratigos; H Gogas; M C Latorre; M Gabree; M Plaka; C N Njauw; K Kypreou; I Mirmigi; I Stefanaki; H Tsao
Journal:  Br J Dermatol       Date:  2011-11-02       Impact factor: 9.302

8.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.

Authors:  Suzanne Carreira; Jane Goodall; Laurence Denat; Mercedes Rodriguez; Paolo Nuciforo; Keith S Hoek; Alessandro Testori; Lionel Larue; Colin R Goding
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

9.  Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.

Authors:  Norman Edward Sharpless; Karuppiah Kannan; Jin Xu; Marcus Wolfram Bosenberg; Lynda Chin
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

10.  Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Authors:  Noah C Jenkins; Jae Jung; Tong Liu; Megan Wilde; Sheri L Holmen; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

View more
  5 in total

1.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

2.  Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis.

Authors:  Emi Dika; Elisabetta Broseghini; Elisa Porcellini; Martina Lambertini; Mattia Riefolo; Giorgio Durante; Phillipe Loher; Roberta Roncarati; Cristian Bassi; Cosimo Misciali; Massimo Negrini; Isidore Rigoutsos; Eric Londin; Annalisa Patrizi; Manuela Ferracin
Journal:  Cell Death Dis       Date:  2021-05-12       Impact factor: 8.469

3.  Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Authors:  Lorena Incorvaia; Giuseppe Badalamenti; Gaetana Rinaldi; Juan Lucio Iovanna; Daniel Olive; Mirna Swayden; Lidia Terruso; Bruno Vincenzi; Fabio Fulfaro; Viviana Bazan; Antonio Russo; Daniele Fanale
Journal:  Ther Adv Med Oncol       Date:  2019-05-13       Impact factor: 8.168

4.  Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.

Authors:  Daniele Fanale; Alessia Fiorino; Lorena Incorvaia; Alessandra Dimino; Clarissa Filorizzo; Marco Bono; Daniela Cancelliere; Valentina Calò; Chiara Brando; Lidia Rita Corsini; Roberta Sciacchitano; Luigi Magrin; Alessia Pivetti; Erika Pedone; Giorgio Madonia; Alessandra Cucinella; Giuseppe Badalamenti; Antonio Russo; Viviana Bazan
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 5.738

5.  CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.

Authors:  Fani Karagianni; Ching-Ni Njauw; Katerina P Kypreou; Aravela Stergiopoulou; Michaela Plaka; Dorothea Polydorou; Vasiliki Chasapi; Leontios Pappas; Ioannis A Stratigos; Gregory Champsas; Peter Panagiotou; Helen Gogas; Evangelos Evangelou; Hensin Tsao; Alexander J Stratigos; Irene Stefanaki
Journal:  Acta Derm Venereol       Date:  2018-10-10       Impact factor: 4.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.